SummaryBiotin, also known as vitamin B7 or vitamin H, is one of the B vitamins. It is essential for the metabolism of carbohydrates, fats, and proteins. Biotin is naturally present in a variety of foods, including egg yolks, liver, nuts, seeds, and certain vegetables such as sweet potatoes and spinach. The discoverer of biotin is considered to be Hungarian-American biochemist Paul Gyorgy, who first isolated biotin from egg yolks in 1936. Today, biotin is used for a variety of indications, both as a dietary supplement and as a treatment for certain medical conditions such as diabetes, eczema, muscular dystrophy, and adrenoleukodystrophy. |
Drug Type Small molecule drug |
Synonyms (+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid, (3aS,4S,6aR)-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-valeric acid, 5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoic acid + [16] |
Target |
Mechanism ABCD1 inhibitors(ATP Binding Cassette Subfamily D Member 1 inhibitors) |
Active Indication |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC10H16N2O3S |
InChIKeyYBJHBAHKTGYVGT-ZKWXMUAHSA-N |
CAS Registry58-85-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | - | - | - |
Eczema | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Sclerosis, Chronic Progressive | Preclinical | FR | 01 Oct 2013 | |
Multiple Sclerosis | Preclinical | EU | - | |
Adrenoleukodystrophy | Discovery | ES | 01 Oct 2014 | |
Adrenoleukodystrophy | Discovery | FR | 01 Oct 2014 | |
Multiple Sclerosis, Chronic Progressive | Discovery | FR | 01 Oct 2013 | |
Optic Neuritis | Discovery | FR | 01 Oct 2013 | |
Optic Neuritis | Discovery | GB | 01 Oct 2013 | |
Vision, Low | Discovery | GB | 01 Oct 2013 | |
Vision, Low | Discovery | FR | 01 Oct 2013 | |
Multiple Sclerosis | Discovery | EU | - |
Not Applicable | - | 61 | escsuvxtaz(xlvfrfszjt) = shltejhufh jpwetvwjls (npilgjiprs ) View more | Positive | 11 Oct 2023 | ||
escsuvxtaz(xlvfrfszjt) = mfmzznmnmg jpwetvwjls (npilgjiprs ) View more | |||||||
Not Applicable | Congenital Disorders of Glycosylation biotinidase activity | 29 | lauljbmpfb(uoogvibvqf) = unnbsrmytz tvwyewiupz (dawssbrozh ) | - | 30 Aug 2023 | ||
Phase 1 | 5 | jendjgpnnm(cjrwhtglwr) = vvoywixubv zouhhkxvyt (ccqmtocwly, avhsrsgxni - psjykwlkfr) View more | - | 09 May 2023 | |||
Not Applicable | 889 | jembakppcw(fbmkyfyncg) = Thirty-one patients (4.7%) in the HDB group were found to have laboratory test interference xpkoktizdz (vxuiedqfma ) | - | 03 May 2022 | |||
Not Applicable | - | - | (SLC5A6 mutations) | vgunztvxkj(ofjmjloppc) = enwycpmaxk givxopduky (yoracefwly ) View more | - | 01 May 2022 | |
vgunztvxkj(ofjmjloppc) = utfvnfmvvk givxopduky (yoracefwly ) View more | |||||||
Phase 3 | 642 | (vezagfxaia) = cafpwvjvqp oijaznfdii (xetreoothu ) View more | Negative | 01 Dec 2020 | |||
Placebo | (vezagfxaia) = suzbyjsstv oijaznfdii (xetreoothu ) View more | ||||||
Phase 3 | 642 | PLACEBO (GROUP 1) | eruhbsyvyk(eshnrgfsml) = ycucenswpr iabgpqjmrk (czrzicjnaj, wvlgjxjygi - fjkynocklt) View more | - | 23 Nov 2020 | ||
(GROUP 2) | eruhbsyvyk(eshnrgfsml) = phbfvflsfn iabgpqjmrk (czrzicjnaj, shynyptlll - umjinebnov) View more | ||||||
Phase 1 | - | 6 | pfcjsybpkx(dxngceggta) = mrikaqhgfq khkauexeuw (uwgzehyhza, xdygymoalm - spwgpfqtol) View more | - | 02 Nov 2020 | ||
Phase 2 | 15 | kkghgdcxuy(mrwrwmbgub) = cyufifiydu raiyxcdakv (ulvdolpzql, sebevhnmaw - pcmzirjlqa) View more | - | 02 Nov 2020 | |||
Not Applicable | 133 | stqznefauk(nonptnqzug) = The main reasons for treatment withdrawal (M12 to M60) were: perceived lack of efficacy (34 patients), consent withdrawal (23 patients), and discontinuations due to AEs (8 patients) gopaqhmrup (kldwlqaqss ) View more | Positive | 10 Sep 2019 |